UA61092C2 - Способ дифференциальной диагностики хронического панкреатита и рака поджелудочной железы - Google Patents
Способ дифференциальной диагностики хронического панкреатита и рака поджелудочной железы Download PDFInfo
- Publication number
- UA61092C2 UA61092C2 UA99073888A UA99073888A UA61092C2 UA 61092 C2 UA61092 C2 UA 61092C2 UA 99073888 A UA99073888 A UA 99073888A UA 99073888 A UA99073888 A UA 99073888A UA 61092 C2 UA61092 C2 UA 61092C2
- Authority
- UA
- Ukraine
- Prior art keywords
- patient
- index
- chronic pancreatitis
- diagnosis
- value
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims abstract description 45
- 208000000668 Chronic Pancreatitis Diseases 0.000 title claims abstract description 34
- 206010033649 Pancreatitis chronic Diseases 0.000 title claims abstract description 34
- 206010061902 Pancreatic neoplasm Diseases 0.000 title claims abstract description 19
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 title claims abstract description 19
- 208000008443 pancreatic carcinoma Diseases 0.000 title claims abstract description 19
- 238000003748 differential diagnosis Methods 0.000 title claims abstract description 18
- 210000000265 leukocyte Anatomy 0.000 claims abstract description 18
- 230000000694 effects Effects 0.000 claims abstract description 16
- 210000004369 blood Anatomy 0.000 claims abstract description 14
- 239000008280 blood Substances 0.000 claims abstract description 14
- 239000000427 antigen Substances 0.000 claims abstract description 11
- 102000036639 antigens Human genes 0.000 claims abstract description 11
- 108091007433 antigens Proteins 0.000 claims abstract description 11
- 238000013508 migration Methods 0.000 claims abstract description 10
- 230000005012 migration Effects 0.000 claims abstract description 10
- 230000007170 pathology Effects 0.000 claims abstract description 7
- ZIIUUSVHCHPIQD-UHFFFAOYSA-N 2,4,6-trimethyl-N-[3-(trifluoromethyl)phenyl]benzenesulfonamide Chemical compound CC1=CC(C)=CC(C)=C1S(=O)(=O)NC1=CC=CC(C(F)(F)F)=C1 ZIIUUSVHCHPIQD-UHFFFAOYSA-N 0.000 claims abstract description 5
- 102000015439 Phospholipases Human genes 0.000 claims abstract description 5
- 108010064785 Phospholipases Proteins 0.000 claims abstract description 5
- 210000000496 pancreas Anatomy 0.000 claims abstract description 5
- INZOTETZQBPBCE-NYLDSJSYSA-N 3-sialyl lewis Chemical compound O[C@H]1[C@H](O)[C@H](O)[C@H](C)O[C@H]1O[C@H]([C@H](O)CO)[C@@H]([C@@H](NC(C)=O)C=O)O[C@H]1[C@H](O)[C@@H](O[C@]2(O[C@H]([C@H](NC(C)=O)[C@@H](O)C2)[C@H](O)[C@H](O)CO)C(O)=O)[C@@H](O)[C@@H](CO)O1 INZOTETZQBPBCE-NYLDSJSYSA-N 0.000 claims abstract 4
- 201000002528 pancreatic cancer Diseases 0.000 claims description 16
- 238000012876 topography Methods 0.000 claims 1
- 238000006243 chemical reaction Methods 0.000 abstract description 8
- 238000003745 diagnosis Methods 0.000 description 14
- 206010028980 Neoplasm Diseases 0.000 description 9
- 208000002193 Pain Diseases 0.000 description 8
- 230000036407 pain Effects 0.000 description 8
- 201000011510 cancer Diseases 0.000 description 6
- 239000003814 drug Substances 0.000 description 6
- 238000011282 treatment Methods 0.000 description 6
- 102000004190 Enzymes Human genes 0.000 description 5
- 108090000790 Enzymes Proteins 0.000 description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
- 229940079593 drug Drugs 0.000 description 5
- 210000000056 organ Anatomy 0.000 description 5
- 239000002872 contrast media Substances 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 230000002183 duodenal effect Effects 0.000 description 4
- 210000001198 duodenum Anatomy 0.000 description 4
- 230000036541 health Effects 0.000 description 4
- 230000001900 immune effect Effects 0.000 description 4
- 238000002559 palpation Methods 0.000 description 4
- 230000000737 periodic effect Effects 0.000 description 4
- 210000002784 stomach Anatomy 0.000 description 4
- 239000004382 Amylase Substances 0.000 description 3
- 102000013142 Amylases Human genes 0.000 description 3
- 108010065511 Amylases Proteins 0.000 description 3
- 206010048714 Gastroduodenitis Diseases 0.000 description 3
- 206010061218 Inflammation Diseases 0.000 description 3
- 208000031481 Pathologic Constriction Diseases 0.000 description 3
- 102000004142 Trypsin Human genes 0.000 description 3
- 108090000631 Trypsin Proteins 0.000 description 3
- 210000001015 abdomen Anatomy 0.000 description 3
- 210000000683 abdominal cavity Anatomy 0.000 description 3
- 235000019418 amylase Nutrition 0.000 description 3
- 238000004364 calculation method Methods 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 206010016766 flatulence Diseases 0.000 description 3
- 230000004054 inflammatory process Effects 0.000 description 3
- 210000004400 mucous membrane Anatomy 0.000 description 3
- 230000007459 negative regulation of leukocyte migration Effects 0.000 description 3
- 210000002445 nipple Anatomy 0.000 description 3
- 210000000277 pancreatic duct Anatomy 0.000 description 3
- 230000036262 stenosis Effects 0.000 description 3
- 208000037804 stenosis Diseases 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 239000012588 trypsin Substances 0.000 description 3
- 206010020751 Hypersensitivity Diseases 0.000 description 2
- 102000004882 Lipase Human genes 0.000 description 2
- 108090001060 Lipase Proteins 0.000 description 2
- 239000004367 Lipase Substances 0.000 description 2
- 206010070834 Sensitisation Diseases 0.000 description 2
- 206010047700 Vomiting Diseases 0.000 description 2
- 208000030961 allergic reaction Diseases 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 210000000013 bile duct Anatomy 0.000 description 2
- 238000004159 blood analysis Methods 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 230000006866 deterioration Effects 0.000 description 2
- 230000005713 exacerbation Effects 0.000 description 2
- 210000000232 gallbladder Anatomy 0.000 description 2
- 210000001035 gastrointestinal tract Anatomy 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 230000003902 lesion Effects 0.000 description 2
- 235000019421 lipase Nutrition 0.000 description 2
- 239000003550 marker Substances 0.000 description 2
- 238000012797 qualification Methods 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 239000000523 sample Substances 0.000 description 2
- 230000008313 sensitization Effects 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 210000003462 vein Anatomy 0.000 description 2
- 230000008673 vomiting Effects 0.000 description 2
- SUBDBMMJDZJVOS-UHFFFAOYSA-N 5-methoxy-2-{[(4-methoxy-3,5-dimethylpyridin-2-yl)methyl]sulfinyl}-1H-benzimidazole Chemical compound N=1C2=CC(OC)=CC=C2NC=1S(=O)CC1=NC=C(C)C(OC)=C1C SUBDBMMJDZJVOS-UHFFFAOYSA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- 208000004998 Abdominal Pain Diseases 0.000 description 1
- 206010000060 Abdominal distension Diseases 0.000 description 1
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 1
- 208000009663 Acute Necrotizing Pancreatitis Diseases 0.000 description 1
- 229930003347 Atropine Natural products 0.000 description 1
- 206010008617 Cholecystitis chronic Diseases 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 208000010201 Exanthema Diseases 0.000 description 1
- 206010017367 Frequent bowel movements Diseases 0.000 description 1
- RKUNBYITZUJHSG-UHFFFAOYSA-N Hyosciamin-hydrochlorid Natural products CN1C(C2)CCC1CC2OC(=O)C(CO)C1=CC=CC=C1 RKUNBYITZUJHSG-UHFFFAOYSA-N 0.000 description 1
- 206010020565 Hyperaemia Diseases 0.000 description 1
- 206010021118 Hypotonia Diseases 0.000 description 1
- 208000007379 Muscle Hypotonia Diseases 0.000 description 1
- 206010028813 Nausea Diseases 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 206010058096 Pancreatic necrosis Diseases 0.000 description 1
- 208000037273 Pathologic Processes Diseases 0.000 description 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 1
- 239000004809 Teflon Substances 0.000 description 1
- 229920006362 Teflon® Polymers 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 230000003187 abdominal effect Effects 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- RKUNBYITZUJHSG-SPUOUPEWSA-N atropine Chemical compound O([C@H]1C[C@H]2CC[C@@H](C1)N2C)C(=O)C(CO)C1=CC=CC=C1 RKUNBYITZUJHSG-SPUOUPEWSA-N 0.000 description 1
- 229960000396 atropine Drugs 0.000 description 1
- 210000003445 biliary tract Anatomy 0.000 description 1
- 238000012742 biochemical analysis Methods 0.000 description 1
- 238000002306 biochemical method Methods 0.000 description 1
- 208000024330 bloating Diseases 0.000 description 1
- 238000009534 blood test Methods 0.000 description 1
- 229960004494 calcium gluconate Drugs 0.000 description 1
- 235000013927 calcium gluconate Nutrition 0.000 description 1
- 239000004227 calcium gluconate Substances 0.000 description 1
- NEEHYRZPVYRGPP-UHFFFAOYSA-L calcium;2,3,4,5,6-pentahydroxyhexanoate Chemical compound [Ca+2].OCC(O)C(O)C(O)C(O)C([O-])=O.OCC(O)C(O)C(O)C(O)C([O-])=O NEEHYRZPVYRGPP-UHFFFAOYSA-L 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 201000001352 cholecystitis Diseases 0.000 description 1
- 210000001953 common bile duct Anatomy 0.000 description 1
- 238000002591 computed tomography Methods 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000013872 defecation Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 238000002405 diagnostic procedure Methods 0.000 description 1
- 230000001079 digestive effect Effects 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 201000005884 exanthem Diseases 0.000 description 1
- 235000021149 fatty food Nutrition 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 210000001156 gastric mucosa Anatomy 0.000 description 1
- 238000002695 general anesthesia Methods 0.000 description 1
- 230000008105 immune reaction Effects 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 208000027866 inflammatory disease Diseases 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- 238000003771 laboratory diagnosis Methods 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 238000002690 local anesthesia Methods 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- -1 maalox Chemical compound 0.000 description 1
- 229940099076 maalox Drugs 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- VAOCPAMSLUNLGC-UHFFFAOYSA-N metronidazole Chemical compound CC1=NC=C([N+]([O-])=O)N1CCO VAOCPAMSLUNLGC-UHFFFAOYSA-N 0.000 description 1
- 230000008693 nausea Effects 0.000 description 1
- 230000009054 pathological process Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 201000001514 prostate carcinoma Diseases 0.000 description 1
- VMXUWOKSQNHOCA-LCYFTJDESA-N ranitidine Chemical compound [O-][N+](=O)/C=C(/NC)NCCSCC1=CC=C(CN(C)C)O1 VMXUWOKSQNHOCA-LCYFTJDESA-N 0.000 description 1
- 229960000620 ranitidine Drugs 0.000 description 1
- 206010037844 rash Diseases 0.000 description 1
- 229940125723 sedative agent Drugs 0.000 description 1
- 239000000932 sedative agent Substances 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 208000019116 sleep disease Diseases 0.000 description 1
- 208000020685 sleep-wake disease Diseases 0.000 description 1
- 235000020994 smoked meat Nutrition 0.000 description 1
- XZNXVSDNACTASG-RZNNTOFGSA-M sodium;3,5-diacetamido-2,4,6-triiodobenzoate;3,5-diacetamido-2,4,6-triiodobenzoic acid;(2r,3r,4r,5s)-6-(methylamino)hexane-1,2,3,4,5-pentol Chemical compound [Na+].CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO.CC(=O)NC1=C(I)C(NC(C)=O)=C(I)C(C(O)=O)=C1I.CC(=O)NC1=C(I)C(NC(C)=O)=C(I)C(C([O-])=O)=C1I XZNXVSDNACTASG-RZNNTOFGSA-M 0.000 description 1
- 210000004872 soft tissue Anatomy 0.000 description 1
- 235000021259 spicy food Nutrition 0.000 description 1
- 201000009032 substance abuse Diseases 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 238000002604 ultrasonography Methods 0.000 description 1
- 230000004580 weight loss Effects 0.000 description 1
Landscapes
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Abstract
Предлагаемый способ дифференциальной диагностики хронического панкреатита и рака поджелудочной железы заключается в том, что определяют показатель активности фосфолипазы А и концентрацию карбогидратного антигена 19-9 в крови пациента, определяют индекс миграции лейкоцитов по реакции торможения лейкоцитов антигенами поджелудочной железы и рассчитывают дифференциальный диагностический показатель по отношению показателя активности фосфолипазы А, увеличенного в сто раз, к произведению индекса миграции лейкоцитов и концентрации карбогидратного антигена 19-9. В зависимости от значения указанного диагностического показателя диагностируют хронический панкреатит, если указанное значение превышает 19,8, рак поджелудочной железы, если указанное значение не превышает 14,4, и отсутствие патологии, если указанное значение находится в пределах от 14,4 до 19,8.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| UA99073888A UA61092C2 (ru) | 1999-07-08 | 1999-07-08 | Способ дифференциальной диагностики хронического панкреатита и рака поджелудочной железы |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| UA99073888A UA61092C2 (ru) | 1999-07-08 | 1999-07-08 | Способ дифференциальной диагностики хронического панкреатита и рака поджелудочной железы |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| UA61092C2 true UA61092C2 (ru) | 2003-11-17 |
Family
ID=34390892
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| UA99073888A UA61092C2 (ru) | 1999-07-08 | 1999-07-08 | Способ дифференциальной диагностики хронического панкреатита и рака поджелудочной железы |
Country Status (1)
| Country | Link |
|---|---|
| UA (1) | UA61092C2 (ru) |
-
1999
- 1999-07-08 UA UA99073888A patent/UA61092C2/ru unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Gross et al. | Autopsy study of the elderly institutionalized patient: review of 234 autopsies | |
| Richards et al. | Noninvasive diagnosis of deep venous thrombosis | |
| Bagaria et al. | Strategies for diagnosis and prevention of venous thromboembolism during pregnancy | |
| Beinart et al. | Obstruction without dilation: importance in evaluating jaundice | |
| Wald et al. | Maternal serum alpha-fetoprotein levels in multiple pregnancy. | |
| Matsumoto et al. | Exercise-loaded indocyanine green fluorescence lymphangiography for diagnosing lymphedema | |
| Vickery et al. | Fever of unknown origin: an algorithmic approach | |
| Koivunen‐Niemelä et al. | Sonography of the Achilles tendon in hypercholesterolaemia | |
| Frasure et al. | Application of point-of-care ultrasound for family medicine physicians for abdominopelvic and soft tissue assessment | |
| Mert et al. | Primary epiploic appendagitis: a case report | |
| RU2157535C1 (ru) | Способ дифференциальной диагностики хронического панкреатита и рака поджелудочной железы | |
| BERK et al. | The present status of imaging of the gallbladder | |
| UA61092C2 (ru) | Способ дифференциальной диагностики хронического панкреатита и рака поджелудочной железы | |
| Kaczmarek et al. | Chubby Infant–Should One Worry? An Infant with Primary lymphedema–Mini Review and Case Report | |
| Halachmi et al. | A review on hematuria in children | |
| Prassopoulos et al. | Renal parenchymal thickness in children measured by computed tomography | |
| JACKMAN et al. | Carcinoma of the large intestine: Diagnostic errors in relation to location of the lesion | |
| EVANS et al. | Early recognition and management of intestinal strangulation | |
| Dongmo et al. | Ultrasound diagnosis of primary epiploic appendagitis: a case report | |
| Bradley et al. | Screening for malignant hyperpyrexia. | |
| Cunningham | Sonographic diameter of the common hepatic duct in sickle cell anemia | |
| RU2220646C2 (ru) | Способ диагностики характера поражения вен нижних конечностей | |
| Hori et al. | Application of Point-of-Care Ultrasound Scanning for the Diagnosis of Perianal Abscess | |
| Chandak et al. | A comparative study of liver abscess: therapeutic aspiration verses continuous catheter drainage | |
| Premkumar | KIMS modification of Alvarado’s score for acute appendicitis |